Department of Medicine, Division of Allergy, Immunology, and Rheumatology, State University of New York at Buffalo, USA
Dr. Mahajan has initiated several new projects that investigate the role of a unique key signaling molecule in the dopaminergic pathway that impacts drug addiction, depression and other neurological disorders. Mahajan has obtained independent research funding from NIDA and the pharmaceutical Pfizer to conduct some of these research projects. Mahajan participates in National and International conferences and seminars where she present her research work. She has authored over 75 publications in several top quality peer reviewed journals and has thus demonstrated a high level of scholarly productivity.